**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 62461

**Manuscript Type:** MINIREVIEWS

**Infantile giant cell hepatitis with autoimmune hemolytic anemia**

Poddighe D *et al*. Infantile GCH and AHA

Dimitri Poddighe, Aidana Madiyeva, Diana Talipova, Balzhan Umirbekova

**Dimitri Poddighe, Aidana Madiyeva, Diana Talipova,** Department ofMedicine, Nazarbayev University School of Medicine, Nur-Sultan 010000, Kazakhstan

**Dimitri Poddighe, Balzhan Umirbekova,** Department of Pediatrics, National Research Center for Maternal and Child Health, Nur-Sultan 010000, Kazakhstan

**Author contributions:** Poddighe D conceived and wrote the manuscript; Madiyeva A and Talipova D contributed to drafting the manuscript and reviewing the relevant literature; Poddighe D and Umirbekova B provided intellectual contribution.

**Corresponding author: Dimitri Poddighe, MD, MSc, PhD, Associate Professor**, Department ofMedicine, Nazarbayev University School of Medicine, Kerei-Zhanibek Str. 5/1, Nur-Sultan 010000, Kazakhstan. dimitri.poddighe@nu.edu.kz

**Received:** January 9, 2021

**Revised:** January 26, 2021

**Accepted:** March 8, 2021

**Published online:**

**Abstract**

Giant cell hepatitis (GCH) is characterized by large and multinucleated (syncytial) hepatocytes in the context of liver inflammation. Infantile GCH is typically associated with autoimmune hemolytic anemia in the absence of any other systemic or organ-specific autoimmune comorbidity. The etiology is unknown; concomitant viral infections (as potential trigger factors) have been identified in a few patients. The pathogenesis reportedly relies upon immune-mediated/autoimmune mechanisms. This condition should be considered in any infant developing Coombs-positive anemia; indeed, anemia usually precedes the development of hepatitis. The clinical course is usually aggressive without the appropriate immunosuppressive therapy, which may include steroids, conventional immunosuppressors (*e.g.*, azathioprine and cyclophosphamide as first-line treatments), intravenous immunoglobulin, and biologics (rituximab). Improvements in medical management (including the availability of rituximab) have significantly reduced the mortality of this condition in the last decade.

**Key Words:** Giant cell hepatitis; Autoimmune hemolytic anemia; Rituximab; Infantile hepatitis; Jaundice; Hyperbilirubinemia

Poddighe D, Madiyeva A, Talipova D, Umirbekova B. Infantile giant cell hepatitis with autoimmune hemolytic anemia. *World J Hepatol* 2021; In press

**Core Tip:** This review discusses the main characteristics of giant cell hepatitis associated with autoimmune hemolytic anemia including etiology, pathogenesis, pathophysiology, clinical aspects, prognosis, and therapy. All of the available case reports and case series have been considered to provide an overall picture of this disease and its general clinical management.

**INTRODUCTION**

Giant cell hepatitis (GCH) refers to a histopathological picture of liver inflammation characterized by large and multinucleated (syncytial) hepatocytes; ≥4-5 nuclei can be seen in the affected cells of the liver parenchyma, along with other features of hepatitis such as lobular fibrotic rearrangements, Kupffer cell hypertrophy, and spotty necrosis[1,2].

In adults, GCH is rare; indeed, it is mainly observed and described in children, mostly in the first years of life. The giant cell transformation of hepatocytes is considered as an altered/dysfunctional regenerative response of hepatocytes in the context of different underlying liver diseases, such as chronic autoimmune hepatitis (AIH), and/or exposure to various noxious agents including drugs and viral infections[2-4].

The histopathological finding of partial or diffuse giant cell transformation of hepatocytes is more frequent in infantile, and in particular, neonatal hepatitis. Indeed, GCH is considered in the differential diagnosis of neonatal cholestasis, where biliary atresia and idiopathic/GCH account for 70% to 80% of all cases; the diagnostic work-up usually includes liver biopsy to achieve a complete and final diagnosis[1,5,6]. GCH is also associated with congenital atresia, and thus, both conditions may coexist. However, neonatal GCH has been described in patients with pathological non-obstructive neonatal jaundice (*e.g.*, blood group incompatibility, hereditary spherocytosis), congenital syphilis, perinatal hemochromatosis, viral infections (*e.g.,* cytomegalovirus, rubella) and metabolic diseases[7,8]. Torbenson *et al*[1] analyzed the etiology of GCH in 62 newborns: 49% of cases were idiopathic, whereas the remaining patients were variably affected with hypopituitarism (15%), biliary atresia (8%), Alagille syndrome (6%), progressive familial intrahepatic cholestasis or other bile salts defects (6%), neonatal hemochromatosis (5%), viral infections (4%), and other diseases (8%, *i.e.* cystic fibrosis, alpha-1-antitrypsin deficiency, severe combined immunodeficiency, AIH)[1].

Infantile GCH is rarely described in patients with post-neonatal hepatitis, and interestingly, is typically associated with autoimmune hemolytic anemia (AHA); this condition is mostly diagnosed in children aged 1 mo to 2 years[9]. Such a pathological association is unusual in post-infantile (childhood and adult) GCH. Indeed, Coombs-positive anemia is found in < 10%-15% cases[10]. Infantile GCH + AHA, as a specific disease pattern, was first recognized in 1981 by Bernard *et al*[11], who described 4 children developing chronic AHA combined with liver disease, which was histologically characterized by severe hepatitis with “diffuse giant cell transformation and extensive fibrosis”[11].

**ETIOLOGY and PATHOGENESIS**

The etiology of GCH + AHA is unknown and specific and/or clear trigger factors have not been identified. Indeed, no individual etiological clues have been identified in most patients, except for some cases in whom viral infections (*e.g.*, paramyxoviruses, varicella-zoster virus, cytomegalovirus) have been reported[4,12-14].

The pathogenesis of GCH + AHA reportedly relies on immune mediated/autoimmune mechanisms, even though this was not included in the classification of pediatric autoimmune liver diseases, according to a recent European Society for Paediatric Gastroenterology Hepatology and Nutrition hepatology committee position statement, which considered three liver disorders: AIH, autoimmune sclerosing cholangitis, and *de novo* AIH after liver transplant[15]. However, several clinical and pathological findings suggest the involvement of immunological mechanisms in infantile GCH, in addition to the AHA comorbidity by itself. Indeed, Nastasio *et al*[16] summarized these aspects, including the response to immunosuppressive therapies, evidence of complement-mediated (C3a- and C5a-driven) hepatocyte injury and liver inflammation, and sporadic association with autoimmune diseases other than AHA[16]. Importantly, the typical histological features of GCH + AHA differ from those described in the aforementioned “classical AIH,” and in fact, autoimmune liver disease-related autoantibodies are absent. However, a “strong immune/autoimmune component” characterizes the pathogenesis of GCH + AHA[17].

Interestingly, Whitington *et al*[18] emphasized that the histopathology of GCH + AHA is similar to that of Gestational Alloimmune Liver Disease (GALD), which accounts for most cases of neonatal hemochromatosis, characterized by a prominent liver giant cell transformation as well[18,19]. The authors showed that, unlike AIH patients, children with GCH + AHA had diffuse and intense C5b-9 complex deposition in the liver, suggesting that the giant cell transformation in these patients was the result of complement-mediated hepatocyte injury, similar to GALD fetuses and newborns, in whom immunoglobulin G-induced complement-mediated hepatocyte injury has been demonstrated[20,21].

These observations support the fact that GCH + AHA is an autoimmune disease in which giant cell transformation is an “unspecific” reactive response to antibody- and complement-mediated hepatocyte injury. Both hepatitis and Coombs-positive anemia appear to be consequences of common systemic B cell immune dysregulation leading to autoantibody production.

**PATHOPHYSIOLOGY and CLINICAL ASPECTS**

In general, GCH + AHA should be suspected in any child aged 1 mo to 2 years, who presents with severe liver disease and anemia. The median age of the onset is about 8 mo, and thus, most cases manifest before 1 year of age[22]. Both males and females can be affected, without a clear gender preponderance; in the largest cases series published by Maggiore *et al*[9], there were 9 male and 7 female patients[9]. If all other case reports and small case series are considered (Table 1)[9,11-14,18,22-41], among the 51 reported patients with infantile GCH + AHA, 25 were female and 19 were male (no gender specification was available for 7 patients).

In detail, GCH should be considered in any infant developing Coombs-positive AHA, especially if jaundice is direct, namely characterized by a component of conjugated bilirubin > 20% of total bilirubin. Indeed, AHA and, in general, all hemolytic anemia cases usually show jaundice deriving from the accumulation of indirect bilirubin, because its excessive production (due to the increased heme catabolism) cannot be readily cleared from the bloodstream and metabolized by the liver[42]. In summary, whereas isolated AHA (which may also show mild-moderate increase of liver enzymes) is characterized by indirect jaundice, GCH is accompanied by clear signs of cholestasis, and thus direct jaundice, in addition to the fact that the increase in liver enzymes is usually very pronounced.

Indeed, the increase in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) is usually at least 15-20 times higher than the upper normal limit of the respective age-related reference range[9], but cases with milder liver enzyme elevation (< 5-10 times the upper normal limit) have been described, especially in the initial phases of hemolytic disease[31,37,39]. In this regard, the development of anemia usually precedes the onset of liver disease by a variable period of time, ranging from 1 mo to > 1 year. Therefore, the diagnosis of GCH + AHA often follows a previous diagnosis of isolated AHA[31].

Moreover, the increase in gamma-glutamyl transferase (GGT) is not usually very pronounced and is often not greater than 2-3 times the age-related upper normal limit[9,38]. Such a GGT increase, especially when associated with mild to moderate AST/ALT abnormalities, could be consistent with several common infectious illnesses (*e.g.*, cytomegalovirus, Epstein-Barr virus, mycoplasma pneumoniae)[43-45], which may also trigger immune-mediated hemolytic diseases, and thus, should be appropriately excluded through diagnostic work-up[46,47].

Therefore, the measurement of ALT, AST, and GGT is recommended in all young children diagnosed with AHA at the onset and during follow-up of the disease. If liver enzymes are highly and/or persistently elevated without any clear (infectious) explanation, these children should undergo liver biopsy to assess the liver’s histopathological features, and in detail, whether GCH is present[9]. In addition to a histopathological picture inconsistent with AIH, these patients are serologically negative for significant titers of anti-mitochondrial, anti-smooth muscle, anti-liver kidney microsomal autoantibodies, and anti-nuclear antibodies[31].

**PROGNOSIS and THERAPY**

The clinical course of GCH + AHA is usually aggressive. According to the analysis of 22 cases reported to 2006, the mortality rate was about 45%. The Italian-French multicentric analysis including 16 pediatric patients (evaluated over a 28-year period and published by Maggiore *et al*[9]) reported a lower mortality rate (25%), probably due to a better therapeutic (*i.e.* immunosuppressive) approach over time. Indeed, if the cases reported after 2011 are specifically considered, only 3 of 29 patients died, which corresponds to an overall mortality rate as low as 10% (Table 1)[9,11-14,18,22-41]. The therapeutic regimens described in these case reports and small case series were widely heterogeneous. Such a discussion goes beyond the scope of this review, but it is worth mentioning that the biological therapy with rituximab was part of the treatment of many more patients after 2011 (rituximab used in 16 of 29 cases) compared to the previous period (rituximab used in 8 of 48 cases), which may have contributed to the reduced mortality in the cases described in the last decade. Indeed, despite an initial response to immunosuppressive therapy, relapses occur in many cases, and liver disease/failure is the main pathological component accounting for a negative prognosis. The hematological component is usually better controlled with immunosuppressive therapy. In fact, persistent and clinically relevant hemolysis has been described in a few patients, who required splenectomy and/or plasmapheresis to control a severe and resistant hematological condition[27,29].

In general, liver disease can be controlled in half of patients with initial immunosuppressive therapy, which may be withdrawn in very few patients. The remaining patients develop more severe disease, which is only partially responsive (or not responsive at all) to immunosuppressive therapy; in some of these cases, the clinical course is rapid and fatal, because of the liver failure by itself and/or its complications, such as severe seizures disorder/encephalopathy and/or concomitant infections[12,29]. Indeed, these children may also develop hemophagocytosis leading to a clinical picture of macrophage activation syndrome, as first described by Hartman *et al*[29].

In those clinical cases with the most severe prognosis, orthotopic liver transplantation (OLT) was also considered. However, the prognosis remained poor. In 1997, Melendez *et al*[28] revised 4 cases undergoing this procedure and 3 of them ultimately died. Importantly, all of these patients showed recurrence of GCH in the transplanted liver within the first few months[28]. A positive transplantation outcome without relapse was described by Kerkar *et al*[48] in a patient developing progressive hepatic encephalopathy. However, despite the association with Coombs-positive anemia, this patient may have not been a case of infantile GCH + AHA, since he had positive anti-liver kidney microsome antibodies, and only partial/patchy giant cell transformation was observed in the liver. Moreover, anemia was associated with thrombocytopenia, suggesting the possibility of type 2 AIH or systemic autoimmune dysfunction leading to several organ immune-mediated disorders, as further supported by the appearance of bullous pemphigoid after liver transplant[48]. Due to constant disease relapse after OLT, such a therapeutic approach has been basically abandoned in the clinical setting of GCH + AHA[12].

Without rapid and appropriate immunosuppressive treatment, the liver function rapidly deteriorates in these patients with infantile GCH + AHA, leading to a progressive and fatal course, as already mentioned. The early institution of an aggressive steroids therapy has beneficial effects on both liver function and autoimmune hemolytic anemia. Combination therapy with steroids and azathioprine/cyclophosphamide is usually the first-line therapy, which is able to significantly reduce mortality in the early phases of disease activity[31]. However, due to the frequent steroid-resistant cases and/or relapses after immunosuppression step-down/withdrawal, several and additional immunosuppressive agents have been variably used (based upon all the available case reports and series), including cyclosporine, tacrolimus, 6-mercaptopurine, mycophenolate and vincristine[12].

In addition to these immunosuppressive drugs, some immunomodulatory therapies have also been used[23,26,29]. In this regard, the first experiences included the use of intravenous immunoglobulins (IVIGs), which were administered according to variable therapeutic schemes, as reviewed by Lega *et al*[34]*.* Actually, these authors used a high-dose regimen (2 g/kg) that was repeated on a monthly basis for more than 6 mo, in association with immunosuppressive therapy[34]. Marsalli *et al*[38] focused their study on IVIG use and concluded that this treatment can help to significantly and rapidly reduce the activity of the liver disease, in combination with prednisone and other immunosuppressive therapies[38]. Some authors also reported the use of plasmapheresis[23,29,30].

However, as mentioned above, the most important advances in infantile GCH + AHA derived from the use of rituximab. In 2004, Gorelik *et al*[30] reported its use to treat the hematological component, but Miloh *et al*[32] first reported a GCH + AHA infant affected with severe liver disease resistant to steroids, azathioprine, sirolimus, and IVIG, who significantly improved after the therapy with rituximab[30,32]. Eventually, several authors reported the successful use of rituximab. For instance, Bakula *et al*[36] reported 4 GCH + AHA infants, who achieved complete remission with rituximab after the failure of the first-line therapy with steroids and azathioprine. Therefore, these authors and others proposed rituximab as the treatment of choice for the early stages of the disease[36,40]. Indeed, unresponsiveness to rituximab is suggested to be more likely when its use is delayed[13]. Additional experiences confirmed the safety and effectiveness of rituximab, even in association with other immunosuppressive agents (*e.g.*, cyclosporine). Moreover, the early treatment could reduce the use of steroids and, thus, prevent several side effects[37]. In some patients, rituximab induced a complete and long-lasting remission and allowed the discontinuation of all immunosuppressive drugs[40]. To conclude, Rovelli *et al*[33] reported a positive result by using alemtuzumab, which is a humanized monoclonal antibody directed against cluster of differentiation 52 (a glycoprotein expressed on circulating T and B lymphocytes and natural-killer cells). Even though long-term remission of the liver disease was reported in this case of GCH + AHA, to date, this is an isolated experience with alemtuzumab.

**CONCLUSION**

Infantile GCH is a clinical condition that should be considered in any infant developing Coombs-positive anemia, in the presence of significant abnormalities of liver function tests and direct hyperbilirubinemia. Indeed, anemia usually precedes the development of hepatitis. This clinical condition requires timely and appropriate immunosuppressive therapy, which may include steroids, conventional immunosuppressors, intravenous immunoglobulin, and biologics (rituximab). Improvements in the medical management (including the availability of rituximab) have significantly reduced the mortality of this condition in the last decade.

**REFERENCES**

1 **Torbenson M**, Hart J, Westerhoff M, Azzam RK, Elgendi A, Mziray-Andrew HC, Kim GE, Scheimann A. Neonatal giant cell hepatitis: histological and etiological findings. *Am J Surg Pathol* 2010; **34**: 1498-1503 [PMID: 20871223 DOI: 10.1097/PAS.0b013e3181f069ab]

2 **Matta B**, Cabello R, Rabinovitz M, Minervini M, Malik S. Post-infantile giant cell hepatitis: A single center's experience over 25 years. *World J Hepatol* 2019; **11**: 752-760 [PMID: 31966907 DOI: 10.4254/wjh.v11.i12.752]

3 **Bihari C**, Rastogi A, Sarin SK. Postinfantile giant cell hepatitis: an etiological and prognostic perspective. *Hepat Res Treat* 2013; **2013**: 601290 [PMID: 23555054 DOI: 10.1155/2013/601290]

4 **Phillips MJ**, Blendis LM, Poucell S, Offterson J, Petric M, Roberts E, Levy GA, Superina RA, Greig PD, Cameron R. Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features. *N Engl J Med* 1991; **324**: 455-460 [PMID: 1988831 DOI: 10.1056/NEJM199102143240705]

5 **Russo P**, Magee JC, Anders RA, Bove KE, Chung C, Cummings OW, Finegold MJ, Finn LS, Kim GE, Lovell MA, Magid MS, Melin-Aldana H, Ranganathan S, Shehata BM, Wang LL, White FV, Chen Z, Spino C; Childhood Liver Disease Research Network (ChiLDReN). Key Histopathologic Features of Liver Biopsies That Distinguish Biliary Atresia From Other Causes of Infantile Cholestasis and Their Correlation With Outcome: A Multicenter Study. *Am J Surg Pathol* 2016; **40**: 1601-1615 [PMID: 27776008 DOI: 10.1097/PAS.0000000000000755]

6 **Dehghani SM**, Haghighat M, Imanieh MH, Geramizadeh B. Comparison of different diagnostic methods in infants with Cholestasis. *World J Gastroenterol* 2006; **12**: 5893-5896 [PMID: 17007060 DOI: 10.3748/wjg.v12.i36.5893]

7 **Fraga JR**, Reichelderfer TE, Scott RB, Said DM. Giant cell hepatitis associated with hereditary spherocytosis. Report of three cases. *Clin Pediatr (Phila)* 1968; **7**: 364-372 [PMID: 5648340 DOI: 10.1177/000992286800700616]

8 **Whitington PF**. Neonatal hemochromatosis: a congenital alloimmune hepatitis. *Semin Liver Dis* 2007; **27**: 243-250 [PMID: 17682971 DOI: 10.1055/s-2007-985069]

9 **Maggiore G**, Sciveres M, Fabre M, Gori L, Pacifico L, Resti M, Choulot JJ, Jacquemin E, Bernard O. Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children. *J Pediatr* 2011; **159**: 127-132.e1 [PMID: 21349541 DOI: 10.1016/j.jpeds.2010.12.050]

10 **Devaney K**, Goodman ZD, Ishak KG. Postinfantile giant-cell transformation in hepatitis. *Hepatology* 1992; **16**: 327-333 [PMID: 1639341 DOI: 10.1002/hep.1840160208]

11 **Bernard O**, Hadchouel M, Scotto J, Odièvre M, Alagille D. Severe giant cell hepatitis with autoimmune hemolytic anemia in early childhood. *J Pediatr* 1981; **99**: 704-711 [PMID: 7299542 DOI: 10.1016/s0022-3476(81)80388-5]

12 **Vajro P**, Migliaro F, Ruggeri C, Di Cosmo N, Crispino G, Caropreso M, Vecchione R. Life saving cyclophosphamide treatment in a girl with giant cell hepatitis and autoimmune haemolytic anaemia: case report and up-to-date on therapeutical options. *Dig Liver Dis* 2006; **38**: 846-850 [PMID: 16266839 DOI: 10.1016/j.dld.2005.09.013]

13 **Baran M**, Özgenç F, Berk Ö, Gökçe D, Kavakli K, Yilmaz F, Şen S, Yağci RV. Giant cell hepatitis and autoimmune hemolytic anemia after chickenpox. *Turk J Gastroenterol* 2010; **21**: 448-451 [PMID: 21332002 DOI: 10.4318/tjg.2010.0135]

14 **Ünal Ş**, Kuşkonmaz B, Balamtekin N, Baysoy G, Aytaç Elmas S, Orhan D, Kale G, Yüce A, Gürakan F, Gümrük F, Çetin M. Autoimmune hemolytic anemia and giant cell hepatitis: Report of three infants. *Turk J Haematol* 2010; **27**: 308-313 [PMID: 27263748 DOI: 10.5152/tjh.2010.55]

15 **Mieli-Vergani G**, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, Fischler B, Gupte G, Hierro L, Indolfi G, Jahnel J, Smets F, Verkade HJ, Hadžić N. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. *J Pediatr Gastroenterol Nutr* 2018; **66**: 345-360 [PMID: 29356770 DOI: 10.1097/MPG.0000000000001801]

16 **Nastasio S**, Sciveres M, Maggiore G. Should Giant Cell Hepatitis With Autoimmune Hemolytic Anemia Be Considered a Pediatric Autoimmune Liver Disease? *J Pediatr Gastroenterol Nutr* 2018; **66**: e137 [PMID: 29394216 DOI: 10.1097/MPG.0000000000001910]

17 **Mieli-Vergani G**, Vergani D. Should Giant Cell Hepatitis With Autoimmune Haemolythic Anaemia Be Considered a Paediatric Autoimmune Liver Disease? *J Pediatr Gastroenterol Nutr* 2018; **66**: e138 [PMID: 29688999 DOI: 10.1097/MPG.0000000000001911]

18 **Whitington PF**, Vos MB, Bass LM, Melin-Aldana H, Romero R, Roy CC, Alvarez F. Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia. *J Pediatr Gastroenterol Nutr* 2014; **58**: 74-80 [PMID: 23969541 DOI: 10.1097/MPG.0b013e3182a98dbe]

19 **Knisely AS**, Mieli-Vergani G, Whitington PF. Neonatal hemochromatosis. *Gastroenterol Clin North Am* 2003; **32**: 877-889, vi-vii [PMID: 14562579 DOI: 10.1016/s0889-8553(03)00050-5]

20 **Pan X**, Kelly S, Melin-Aldana H, Malladi P, Whitington PF. Novel mechanism of fetal hepatocyte injury in congenital alloimmune hepatitis involves the terminal complement cascade. *Hepatology* 2010; **51**: 2061-2068 [PMID: 20512994 DOI: 10.1002/hep.23581]

21 **Whitington PF**, Pan X, Kelly S, Melin-Aldana H, Malladi P. Gestational alloimmune liver disease in cases of fetal death. *J Pediatr* 2011; **159**: 612-616 [PMID: 21592512 DOI: 10.1016/j.jpeds.2011.03.048]

22 **Raj S**, Stephen T, Debski RF. Giant cell hepatitis with autoimmune hemolytic anemia: a case report and review of pediatric literature. *Clin Pediatr (Phila)* 2011; **50**: 357-359 [PMID: 21436150 DOI: 10.1177/0009922810379501]

23 **Imgrueth M**, Wagner HP, Pipczynski-Suter K, Beguin L, Wyss M, Pfister AM, Stock HK, Oetliker O. Plasma exchange: an important part of the therapeutic procedure in a small child with autoimmune hemolytic anemia. *Acta Paediatr Scand* 1986; **75**: 1037-1041 [PMID: 3564965 DOI: 10.1111/j.1651-2227.1986.tb10339.x]

24 **Brichard B**, Sokal E, Gosseye S, Buts JP, Gadisseux JF, Cornu G. Coombs-positive giant cell hepatitis of infancy: effect of steroids and azathioprine therapy. *Eur J Pediatr* 1991; **150**: 314-317 [PMID: 2044600 DOI: 10.1007/BF01955929]

25 **Weinstein T**, Valderrama E, Pettei M, Levine J. Early steroid therapy for the treatment of giant cell hepatitis with autoimmune hemolytic anemia. *J Pediatr Gastroenterol Nutr* 1993; **17**: 313-316 [PMID: 8271134 DOI: 10.1097/00005176-199310000-00015]

26 **Perez-Atayde AR**, Sirlin SM, Jonas M. Coombs-positive autoimmune hemolytic anemia and postinfantile giant cell hepatitis in children. *Pediatr Pathol* 1994; **14**: 69-77 [PMID: 8159622 DOI: 10.3109/15513819409022027]

27 **Choulot JJ**, Parent Y, Etcharry F, Saint-Martin J, Mensire A. [Giant cell hepatitis and autoimmune hemolytic anemia: efficacy of splenectomy on hemolysis]. *Arch Pediatr* 1996; **3**: 789-791 [PMID: 8998533 DOI: 10.1016/0929-693x(96)82162-2]

28 **Melendez HV**, Rela M, Baker AJ, Ball C, Portmann B, Mieli-Vergani G, Heaton ND. Liver transplant for giant cell hepatitis with autoimmune haemolytic anaemia. *Arch Dis Child* 1997; **77**: 249-251 [PMID: 9370907 DOI: 10.1136/adc.77.3.249]

29 **Hartman C**, Berkowitz D, Brik R, Arad A, Elhasid R, Shamir R. Giant cell hepatitis with autoimmune hemolytic anemia and hemophagocytosis. *J Pediatr Gastroenterol Nutr* 2001; **32**: 330-334 [PMID: 11345187 DOI: 10.1097/00005176-200103000-00020]

30 **Gorelik M**, Debski R, Frangoul H. Autoimmune hemolytic anemia with giant cell hepatitis: case report and review of the literature. *J Pediatr Hematol Oncol* 2004; **26**: 837-839 [PMID: 15591908]

31 **Kashyap R**, Sarangi JN, Choudhry VP. Autoimmune hemolytic anemia in an infant with giant cell hepatitis. *Am J Hematol* 2006; **81**: 199-201 [PMID: 16493610 DOI: 10.1002/ajh.20414]

32 **Miloh T**, Manwani D, Morotti R, Sukru E, Shneider B, Kerkar N. Giant cell hepatitis and autoimmune hemolytic anemia successfully treated with rituximab. *J Pediatr Gastroenterol Nutr* 2007; **44**: 634-636 [PMID: 17460499 DOI: 10.1097/MPG.0b013e31802e9739]

33 **Rovelli A**, Corti P, Beretta C, Bovo G, Conter V, Mieli-Vergani G. Alemtuzumab for giant cell hepatitis with autoimmune hemolytic anemia. *J Pediatr Gastroenterol Nutr* 2007; **45**: 596-599 [PMID: 18030239 DOI: 10.1097/MPG.0b013e318033169f]

34 **Lega S**, Maschio M, Taddio A, Maggiore G, Ventura A. Giant cell hepatitis with Coombs-positive haemolytic anaemia: steroid sparing with high-dose intravenous immunoglobulin and cyclosporine. *Acta Paediatr* 2013; **102**: e137-e139 [PMID: 23205764 DOI: 10.1111/apa.12114]

35 **Bouguila J**, Mabrouk S, Tilouche S, Bakir D, Trabelsi A, Hmila A, Boughammoura L. Giant cell hepatitis with autoimmune hemolytic anemia in a nine month old infant. *World J Hepatol* 2013; **5**: 226-229 [PMID: 23671728 DOI: 10.4254/wjh.v5.i4.226]

36 **Bakula A**, Socha P, Klaudel-Dreszler M, Karolczyk G, Wozniak M, Rutynowska-Pronicka O, Matysiak M. Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach. *J Pediatr Gastroenterol Nutr* 2014; **58**: 669-673 [PMID: 24792633 DOI: 10.1097/MPG.0000000000000270]

37 **Paganelli M**, Patey N, Bass LM, Alvarez F. Anti-CD20 treatment of giant cell hepatitis with autoimmune hemolytic anemia. *Pediatrics* 2014; **134**: e1206-e1210 [PMID: 25201797 DOI: 10.1542/peds.2014-0032]

38 **Marsalli G**, Nastasio S, Sciveres M, Calvo PL, Ramenghi U, Gatti S, Albano V, Lega S, Ventura A, Maggiore G. Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: A multicenter study. *Clin Res Hepatol Gastroenterol* 2016; **40**: 83-89 [PMID: 26138133 DOI: 10.1016/j.clinre.2015.03.009]

39 **Cho MH**, Park HS, Han HS, Bae SH. Giant cell hepatitis with autoimmune hemolytic anemia in a Korean infant. *Pediatr Int* 2016; **58**: 628-631 [PMID: 26841192 DOI: 10.1111/ped.12874]

40 **Matarazzo L**, Di Chio T, Nastasio S, Tommasini A, Ventura A, Maggiore G. B-cell depletion induces prolonged remission in patients with giant cell hepatitis and autoimmune hemolytic anemia. *Clin Res Hepatol Gastroenterol* 2020; **44**: 66-72 [PMID: 31076361 DOI: 10.1016/j.clinre.2019.03.010]

41 **Kim YH**, Kim JW, Lee EJ, Kang GH, Kang HJ, Moon JS, Ko JS. Successful Treatment of a Korean Infant with Giant Cell Hepatitis with Autoimmune Hemolytic Anemia Using Rituximab. *Pediatr Gastroenterol Hepatol Nutr* 2020; **23**: 180-187 [PMID: 32206631 DOI: 10.5223/pghn.2020.23.2.180]

42 **Phillips J**, Henderson AC. Hemolytic Anemia: Evaluation and Differential Diagnosis. *Am Fam Physician* 2018; **98**: 354-361 [PMID: 30215915]

43 **Poddighe D**. Mycoplasma pneumoniae-related hepatitis in children. *Microb Pathog* 2020; **139**: 103863 [PMID: 31712120 DOI: 10.1016/j.micpath.2019.103863]

44 **Poddighe D**, Sazonov V. Acute acalculous cholecystitis in children. *World J Gastroenterol* 2018; **24**: 4870-4879 [PMID: 30487697 DOI: 10.3748/wjg.v24.i43.4870]

45 **Mantadakis E**, Chatzimichael E, Kontekaki E, Panopoulou M, Martinis G, Tsalkidis A. EBV-related Cold Agglutinin Disease Presenting With Conjugated Hyperbilirubinemia: A Pediatric Case Report and Mini Review. *J Pediatr Hematol Oncol* 2019; **41**: 324-327 [PMID: 29683945 DOI: 10.1097/MPH.0000000000001184]

46 **Poddighe D**. Extra-pulmonary diseases related to Mycoplasma pneumoniae in children: recent insights into the pathogenesis. *Curr Opin Rheumatol* 2018; **30**: 380-387 [PMID: 29432224 DOI: 10.1097/BOR.0000000000000494]

47 **Murray JC**, Bernini JC, Bijou HL, Rossmann SN, Mahoney DH Jr, Morad AB. Infantile cytomegalovirus-associated autoimmune hemolytic anemia. *J Pediatr Hematol Oncol* 2001; **23**: 318-320 [PMID: 11464992 DOI: 10.1097/00043426-200106000-00018]

48 **Kerkar N**, Cohen S, Dugan C, Morotti RA, Phelps RG, Herold B, Shneider B, Emre S. Bullous pemphigoid after liver transplantation for liver failure. *Liver Transpl* 2006; **12**: 1705-1710 [PMID: 17058253 DOI: 10.1002/Lt.20930]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** European Society of Pediatric Gastroenterology, Hepatology and Nutrition, No. 1555.

**Peer-review started:** January 9, 2021

**First decision:** January 25, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Kazakhstan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Khaliq S **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:**

**Table 1** **Overview of the demographic features and outcome in patients with infantile giant cell hepatitis and autoimmune hemolytic anemia**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Clinical cases, *n*** | **Age in mo** | **Gender** | **Outcome** | **Rituximab** | **Follow-up in mo** | | **Cause of death** |
| **Before 2011 (case reports/series providing individual data on infantile GCH + AHA)** | | | | | | | | |
| Bernard *et al*[11], France, 1981 | 1 | 10 | F | Fatal | N | - | Liver failure | |
|  | 2 | 9 | M | Fatal | N | - | Liver failure | |
|  | 3 | 24 | M | Fatal | N | - | Liver failure | |
|  | 4 | 6.5 | M | Alive | N | N/A | - | |
| Imgrueth *et al*[23],Switzerland, 1986 | 5 | 5 | F | Alive | N | 9 | - | |
|  | 6 | 8 | M | Alive | N | 24 | - | |
| Brichard *et al*[24],Belgium, 1991 | 7 | 7 | F | Fatal | N | - | Encephalopathy | |
| Weinstein *et al*[25], United States, 1993 | 8 | 5 | F | Alive | N | 30 | - | |
| Perez-Atayde *et al*[26],United States, 1994 | 9 | 23 | F | Fatal | N | - | Sepsis | |
|  | 10 | 9 | M | Alive | N | 8 | - | |
| Choulot *et al*[27],France, 1996 | 11 | 15 | M | Alive | N | 12 yr | - | |
| Melendez *et al*[28], United Kingdom, 1997 | 12 | 8 | M | Fatal | N | - | Liver and renal failure | |
| Hartman *et al*[29], Israel, 2001 | 13 | 6 | M | Fatal | N | - | Liver failure | |
| Gorelik *et al*[30], United States, 2004 | 14 | 4 | F | Alive | Y | 36 | - | |
| Kashyap *et al*[31], India, 2006 | 15 | 4 | F | Alive | N | 2 | - | |
| Vajro *et al*[12], Italy, 2006 | 16 | 10 | F | Alive | N | 36 | - | |
| Miloh *et al*[32], United States, 2007 | 17 | 2 | M | Alive | Y | 24 | - | |
| Rovelli *et al*[33], Italy, 2007 | 18 | 14 | M | Alive | Y | 48 | - | |
| Baran *et al*[13], Turkey, 2010 | 19 | 3 | F | Fatal | Y | - | Sepsis and renal failure | |
| Ünal *et al*[14], Turkey, 2010 | 20 | 2 | F | Fatal | Y | - | Sepsis | |
|  | 21 | 6 | M | Fatal | N | - | N/A | |
|  | 22 | 11 | M | Alive | Y | 18 | - | |
| **Maggiore *et al*[9] (largest case series providing aggregate data on infantile GCH + AHA)** | | | | | | | | |
| Maggiore *et al*[9], Italy, 2011 | 16 cases | 2.5-17 | M (*n* = 9); F (*n* = 7) | Alive (*n* = 12); Fatal (*n* = 4) | Y (*n* = 2); N (*n* = 10) | 2-28 yr | OLT (*n* = 1); Sepsis (*n* = 3) | |
| **After 2011 (case reports/series providing individual data on infantile GCH + AHA)** | | | | | | | | |
| Raj *et al*[22], United States, 2011 | 1 | 6 | F | Alive | N | 30 | - | |
| Lega *et al*[34], Italy, 2013 | 2 | 8 | M | Alive | N | 6 | - | |
| Bouguila *et al*[35], Tunisia, 2013 | 3 | 9 | N/A | Fatal | N | - | Sepsis | |
| Whitington *et al*[18], Canada & United States, 2014 | 4 | 22 | F | Alive | Y | 48 | - | |
|  | 5 | 14 | F | Alive | Y | 48 | - | |
|  | 6 | 6 | F | Alive | N | 48 | - | |
|  | 7 | 4 | F | Fatal | N | - | N/A | |
|  | 8 | 6 | M | Alive | Y | 36 | - | |
| Bakula *et al*[36], Poland, 2014 | 9 | 7 | N/A | Alive | Y | 30 | - | |
|  | 10 | 8 | N/A | Alive | Y | 26 | - | |
|  | 11 | 2 | N/A | Alive | Y | 5 | - | |
|  | 12 | 12 | N/A | Alive | Y | 76 | - | |
|  | 13 | 7 | N/A | Fatal | N | - | Hemophagocytosis (after HSCT) | |
| Paganelli *et al*[37], Italy, 2014 | 14 | 3 | F | Alive | Y | N/A1 | - | |
|  | 15 | 14 | F | Alive | Y | N/A1 | - | |
|  | 16 | 12 | F | Alive | Y | N/A1 | - | |
|  | 17 | 16 | M | Alive | Y | N/A1 | - | |
| Marsalli *et al*[38], Italy, 2016 | 18 | 5 | F | Alive | N | N/A1 | - | |
|  | 19 | 8 | M | Alive | N | N/A1 | - | |
|  | 20 | 10 | F | Alive | N | N/A1 | - | |
|  | 21 | 10 | F | Alive | N | N/A1 | - | |
|  | 22 | 6 | F | Alive | Y | N/A1 | - | |
|  | 23 | 7 | F | Alive | N | N/A1 | - | |
|  | 24 | 8 | M | Alive | N | N/A1 | - | |
| Cho *et al*[39], South Korea, 2016 | 25 | 2 | N/A | Alive | N | 36 | - | |
| Matarazzo *et al*[40], Italy, 2020 | 26 | 5 | F | Alive | Y | 141 | - | |
|  | 27 | 9 | F | Alive | Y | 91 | - | |
|  | 28 | 8 | M | Alive | Y | 76 | - | |
| Kim *et al*[41], South Korea, 2020 | 29 | 7 | M | Alive | Y | 19 | - | |

1The authorsdid not provide the follow-up length for individual patients; however, they provided general information on follow-up in their respective case series (Paganelli *et al*[37]: “At last follow-up visit, all patients were alive with their native liver 2 to 16 year after disease presentation”; Marsalli *et al*[38]: “Follow-up (median 17.4 mo, range 7-24 mo).” F: Female; HSCT: Hematopoietic stem cell transplantation; M: Male; N/A: Not available; N: No; OLT: Orthotopic liver transplantation; Y: Yes.